Related Experiment Video

Updated: May 25, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Drug transporter regulation in tumors by DNA methylation

Oliver Zolk1, Martin F Fromm

  • 1Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstrasse 17, 91054 Erlangen, Germany. fromm@pharmakologie.med.uni-erlangen.de.

Genome Medicine
|February 2, 2012
PubMed

Insights

Epigenetic silencing of the organic cation transporter SLC22A1 in liver cancer may explain varied drug responses. This finding offers new strategies for optimizing cancer pharmacotherapy.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Aberrant DNA methylation is a key feature of cancer, often silencing tumor suppressor genes.
  • The multispecific organic cation transporter SLC22A1 is crucial for cellular uptake of various anticancer drugs.

Purpose of the Study:

  • To investigate the role of epigenetic silencing of SLC22A1 in hepatocellular carcinoma.
  • To explore the implications of SLC22A1 alterations for anticancer drug efficacy and treatment variability.

Main Methods:

  • Analysis of DNA methylation patterns in hepatocellular carcinoma tissues.
  • Assessment of SLC22A1 expression levels in relation to methylation status.
  • Correlation of transporter expression with patient response to chemotherapy.

Main Results:

  • Evidence of epigenetic silencing of SLC22A1 via promoter hypermethylation in hepatocellular carcinoma.
  • Reduced SLC22A1 expression is associated with altered drug uptake.
  • This silencing mechanism contributes to variability in patient response to anticancer therapies.

Conclusions:

  • Epigenetic silencing of SLC22A1 represents a novel mechanism influencing hepatocellular carcinoma treatment outcomes.
  • Targeting or understanding SLC22A1 function could lead to improved pharmacotherapy strategies for liver cancer.

More Related Videos

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images09:42

Immunostaining for DNA Modifications: Computational Analysis of Confocal Images

Published on: September 7, 2017

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution13:47

Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution

Published on: February 24, 2015

Related Concept Videos

Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Epigenetic Regulation01:46

Epigenetic Regulation

Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...